Chemokine receptors as specific anti-inflammatory targets in peripheral nerves

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 141-153

  Ubogu, Eroboghene E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune neuropathies; Chemokine receptors; Chemokines; Neuroinflammation; Neuropathic pain; Peripheral nerves

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,5 ANHYDRO 2,3 DIDEOXY 3 [[3 [[7,8 DIHYDRO 3 (TRIFLUOROMETHYL) 1,6 NAPHTHYRIDIN 6(5H) YL]CARBONYL] 3 ISOPROPYLCYCLOPENTYL]AMINO] 4 O METHYLPENTITOL; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; AMG 487; AZATHIOPRINE; AZD5672; BAY86 5047; BKT140; BMS 936564; CCX 282; CCX140; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; GSK1325756; GW776994; IMMUNOGLOBULIN; INCB 3284; INCB 8696; MARAVIROC; METHOTREXATE; MLN 1202; MLN 3701; MOGAMULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PF 4136309; PLERIXAFOR; SB 656933; SCH 527123; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE NEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG TARGETING; EFFECTOR CELL; ENDOMETRIOSIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LUPUS VULGARIS; LYMPHOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEURITIS; NEUROPATHIC PAIN; NOCICEPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PSORIASIS; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; VASCULAR RESTENOSIS; VASCULITIC NEUROPATHY;

EID: 79956285938     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011795564124     Document Type: Article

References (68)

1. Ubogu, E.; Cossoy, M. and Ransohoff, R. (2006) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci., 27, 48-55.
2. Neel, N.; Schutyser, E.; Sai, J.; Fan, G. and Richmond, A. (2005) Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev., 16, 637-658.
3. Charo, I. and Ransohoff, R. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 354, 610-621.
4. Mackay, C. (2008) Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat. Immunol., 9, 988-998.
5. Horuk, R. (2009) Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov., 8, 23-33.
6. Cardona, A.E.; Li, M.; Liu, L.; Savarin, C. and Ransohoff, R.M. (2008) Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol., 84, 587-594.
7. Li, M. and Ransohoff, R.M. (2008) Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol., 84, 116-131.
8. White, F.A.; Feldman, P. and Miller, R. J. (2009) Chemokine signaling and the management of neuropathic pain. Mol. Interv., 9, 188-195.
9. Hartung, H.; Willison, H. and Kieseier, B. (2002) Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr. Opin. Neurol., 15, 571-577.
10. Kieseier, B.; Kiefer, R.; Gold, R.; Hemmer, B.; Willison, H. and Hartung, H. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve, 30, 131-156.
11. Hughes, R. and Cornblath, D. (2005) Guillain-Barré syndrome. Lancet, 366, 1653-1666.
12. Meyer, Z U.; Hörste, G.; Hartung, H. and Kieseier, B. (2007) From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat. Clin. Pract. Neurol., 3, 198-211.
13. Teitelbaum, J.S. and Borel, C.O. (1994) Respiratory dysfunction in Guillain-Barré syndrome. Clin. Chest Med., 15, 705-714.
14. Orlikowski, D.; Prigent, H.; Sharshar, T.; Lofaso, F. and Raphael, J.C. (2004) Respiratory dysfunction in Guillain-Barré Syndrome. Neurocrit. Care, 1, 415-422.
15. Frenzen, P. (2008) Economic cost of Guillain-Barré syndrome in the United States. Neurology, 71, 21-27.
16. Kieseier, B.; Dalakas, M. and Hartung, H. (2002) Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology, 59, S7-12.
17. Chia, L.; Fernandez, A.; Lacroix, C.; Adams, D.; Planté, V. and Said, G. (1996) Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain, 119, 1091-1098.
18. Bouchard, C.; Lacroix, C.; Planté, V.; Adams, D.; Chedru, F.; Guglielmi, J. and Said, G. (1999) Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology, 52, 498-503.
19. Rizzuto, N.; Morbin, M.; Cavallaro, T.; Ferrari, S.; Fallahi, M. and Galiazzo, R.S. (1998) Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol., 96, 603-609.
20. Bonetti, B.; Invernizzi, F.; Rizzuto, N.; Bonazzi, M.L.; Zanusso, G.L.; Chinaglia, G. and Monaco, S. (1997) T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy. J. Neuroimmunol., 73, 145-154.
21. Pagnoux, C. and Guillevin, L. (2005) Peripheral neuropathy in systemic vasculitides. Curr. Opin. Rheumatol., 17, 41-48.
22. Said, G. and Lacroix, C. (2005) Primary and secondary vasculitic neuropathy. J. Neurol., 252, 633-641.
23. Press, R.; Pashenkov, M.; Jin, J.P. and Link, H. (2003) Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Clin. Immunol., 23, 259-267.
24. Sainaghi, P.P.; Collimedaglia, L.; Alciato, F.; Leone, M.A.; Naldi, P.; Molinari, R.; Monaco, F. and Avanzi, G.C. (2010) The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine, 51, 138-143.
25. Kieseier, B.C.; Tani, M.; Mahad, D.; Oka, N.; Ho, T.; Woodroofe, N.; Griffin, J.W.; Toyka, K.V.; Ransohoff, R.M. and Hartung, H.P. (2002) Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain, 125, 823-834.
26. Saadoun, D.; Bieche, I.; Maisonobe, T.; Asselah, T.; Laurendeau, I.; Piette, J.C.; Vidaud, M. and Cacoub, P. (2005) Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum., 52, 2917-2925.
27. Kinter, J.; Broglio, L.; Steck, A.J.; Tolnay, M.; Fuhr, P.; Latov, N.; Kalbermatten, D.; Sinnreich, M.; Schaeren-Wiemers, N. and Renaud, S. (2010) Gene expression profiling in nerve biopsy of vasculitic neuropathy. J. Neuroimmunol., 225, 184-189.
28. Fujioka, T. and Purev, E.; Rostami, A. (1999) Chemokine mRNA expression in the cauda equina of Lewis rats with experimental allergic neuritis. J. Neuroimmunol., 97, 51-59.
29. Kieseier, B.C.; Krivacic, K.; Jung, S.; Pischel, H.; Toyka, K.V.; Ransohoff, R.M. and Hartung, H.P. (2000) Sequential expression of chemokines in experimental autoimmune neuritis. J. Neuroimmunol., 110, 121-129.
30. Orlikowski, D.; Chazaud, B.; Plonquet, A.; Poron, F.; Sharshar, T.; Maison, P.; Raphael, J.C.; Gherardi, R.K. and Creange, A. (2003) Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barre syndrome and experimental autoimmune neuritis. J. Neuroimmunol., 134, 118-127.
31. Xia, R.; Yosef, N. and Ubogu, E. (2010) Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. J. Neuroimmunol., 219, 54-63.
32. Xia, R.H.; Yosef, N. and Ubogu, E.E. (2010) Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. Neuropathol. Appl. Neurobio., 36, 388-398.
33. Duan, R.; Chen, Z.; Bao, L.; Quezada, H.; Nennesmo, I.; Winblad, B. and Zhu, J. (2004) CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis. Neurobiol. Dis., 16, 630-637.
34. Bennett, G. (1998) Neuropathic pain: new insights, new interventions. Hosp. Pract. (Minneap)., 33, 95-98, 101-104, 107-110 passim.
35. Moalem, G. and Tracey, D. (2006) Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev., 51, 240-264.
36. Dworkin, R. (2002) An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin. J. Pain, 18, 343-349.
37. Argoff, C.; Cole, B.; Fishbain, D. and Irving, G. (2006) Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo. Clin. Proc., 81, S3-S11.
38. Perkins, N. and Tracey, D. (2000) Hyperalgesia due to nerve injury: role of neutrophils. Neuroscience, 101, 745-757.
39. Thacker, M.; Clark, A.; Marchand, F. and McMahon, S. (2007) Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth. Analg., 105, 838-847.
40. White, F.A. and Miller, R.J. (2010) Insights into the regulation of chemokine receptors by molecular signaling pathways: functional roles in neuropathic pain. Brain Behav. Immun., 24, 859-865.
41. Kiguchi, N.; Maeda, T.; Kobayashi, Y.; Fukazawa, Y. and Kishioka, S. (2010) Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain, 149, 305-315.
42. Schreiber, R.; Krivacic, K.; Kirby, B.; Vaccariello, S.; Wei, T.; Ransohoff, R. and Zigmond, R. (2001) Monocyte chemoattractant protein (MCP)-1 is rapidly expressed by sympathetic ganglion neurons following axonal injury. Neuroreport, 12, 601-606.
43. Abbadie, C.; Lindia, J.A.; Cumiskey, A.M.; Peterson, L.B.; Mudgett, J.S.; Bayne, E.K.; DeMartino, J.A.; MacIntyre, D.E. and Forrest, M.J. (2003) Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. USA, 100, 7947-7952.
44. Abbadie, C.; Bhangoo, S.; De Koninck, Y.; Malcangio, M.; Melik-Parsadaniantz, S. and White, F.A. (2009) Chemokines and pain mechanisms. Brain Res. Rev., 60, 125-134.
45. Jung, H.; Bhangoo, S.; Banisadr, G.; Freitag, C.; Ren, D.; White, F.A. and Miller, R.J. (2009) Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J. Neurosci., 29, 8051-8062.
46. White, F.; Jung, H. and Miller, R. (2007) Chemokines and the pathophysiology of neuropathic pain. Proc. Natl. Acad. Sci. USA, 104, 20151-20158.
47. Gosselin, R.D.; Dansereau, M.A.; Pohl, M.; Kitabgi, P.; Beaudet, N.; Sarret, P. and Mélik, P.S. (2008) Chemokine network in the nervous system: a new target for pain relief. Curr. Med. Chem., 15, 2866-2875.
48. White, F. and Wilson, N. (2010) Opiate-induced hypernociception and chemokine receptors. Neuropharmacology, 58, 35-37.
49. Keswani, S.C.; Polley, M.; Pardo, C.A.; Griffin, J.W.; McArthur, J.C. and Hoke, A. (2003) Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann. Neurol., 54, 287-296.
50. Verge, G.M.; Milligan, E.D.; Maier, S.F.; Watkins, L.R.; Naeve, G.S. and Foster, A.C. (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci., 20, 1150-1160.
51. Staniland, A.A.; Clark, A.K.; Wodarski, R.; Sasso, O.; Maione, F.; D'Acquisto, F. and Malcangio, M. (2010) Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J. Neurochem., 114, 1143-1157.
52. Clark, A.K.; Yip, P.K.; Malcangio, M. (2009) The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J. Neurosci., 29, 6945-6954.
53. Scott, D.L.; Wolfe, F. and Huizinga, T.W. (2010) Rheumatoid arthritis. Lancet, 376, 1094-1108.
54. Di Pauli, F.; Berger, T. and Reindl, M. (2009) Monoclonal antibodies in the treatment of multiple sclerosis. Curr. Med. Chem., 16, 4858-4868.
55. Bickston, S.J. and Muniyappa, K. (2010) Natalizumab for the treatment of Crohn's disease. Expert Rev. Clin. Immunol., 6, 513-519.
56. O'Hayre, M.; Salanga, C.L.; Handel, T.M. and Hamel, D.J. (2010) Emerging concepts and approaches for chemokine-receptor drug discovery. Expert Opin. Drug Discov., 5, 1109-1122.
57. Perry, C.M. (2010) Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs, 70, 1189-1213.
58. Kessans, M.R.; Gatesman, M.L. and Kockler, D.R. (2010) Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy, 30, 485-492.
59. Gladue, R.P.; Brown, M.F. and Zwillich, S.H. (2010) CCR1 antagonists: what have we learned from clinical trials. Curr. Top. Med. Chem., 10, 1268-1277.
60. Yosef, N.; Xia, R. and Ubogu, E. (2010) Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells. J. Neuropathol. Exp. Neurol., 69, 82-97.
61. Xia, R.; Yosef, N. and Ubogu, E. (2010) Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: technical aspects and normative data. Muscle Nerve, 41, 850-856.
62. Olsson, Y. (1990) Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit. Rev. Neurobiol., 5, 265-311.
63. Reina, M.; López, A.; Villanueva, M.; de Andrés, J. and León, G. (2000) [Morphology of peripheral nerves, their sheaths, and their vascularization]. Rev. Esp. Anestesiol. Reanim., 47, 464-475.
64. Reina, M.; López, A.; Villanueva, M.; De Andrés, J. and Machés, F. (2003) [The blood-nerve barrier in peripheral nerves]. Rev. Esp. Anestesiol. Reanim., 50, 80-86.
65. Olsson, Y. (1968) Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol., 10, 26-33.
66. Lacotte, S.; Brun, S.; Muller, S. and Dumortier, H. (2009) CXCR3, inflammation, and autoimmune diseases. Ann. N.Y. Acad. Sci., 1173, 310-317.
67. Deshmane, S.; Kremlev, S.; Amini, S. and Sawaya, B. (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon. Cytokine Res., 29, 313-326.
68. Mahad, D.; Callahan, M.; Williams, K.; Ubogu, E.; Kivisäkk, P.; Tucky, B.; Kidd, G.; Kingsbury, G.; Chang, A.; Fox, R.; Mack, M.; Sniderman, M.; Ravid, R.; Staugaitis, S.; Stins, M. and Ransohoff, R. (2006) Modulating CCR2 and CCL2 at the bloodbrain barrier: relevance for multiple sclerosis pathogenesis. Brain, 129, 212-223.